{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:24:20Z","timestamp":1786973060287,"version":"build-2736575974"},"reference-count":30,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:00:00Z","timestamp":1786752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objectives: Chemotherapy drug (ChD)-induced maculopapular eruptions (MPEs) may interrupt optimal cancer treatment when no equally effective alternative therapy is available. Evidence supporting rapid drug desensitization (RDD) for delayed-type MPE remains scarce. We aimed to evaluate the feasibility and safety of RDD in patients with ChD-induced MPE. Methods: Adult patients with ChD-induced MPE who underwent RDD between January 2021 and January 2024 were evaluated. Delayed MPE recurrence was assessed until the subsequent chemotherapy cycle. Results: A total of 63 RDD procedures were performed in 10 patients with ChD-induced MPE, most commonly triggered by taxanes and platinum agents. The median onset of the index reaction was 60.0 h (24.0\u2013336.0), and delayed intradermal tests were positive in 2 of 9 tested patients (22.2%). No delayed MPE recurrences were observed during the predefined follow-up period until the subsequent chemotherapy cycle. Immediate breakthrough reactions occurred in 3 of 10 patients (30.0%), corresponding to 17 of 63 RDD procedures (27.0%), and were limited to mild flushing and pruritus that resolved with antihistamines with or without low-dose corticosteroids. All RDD procedures were successfully completed without severe systemic reactions, and all patients were discharged on the same day. Conclusions: In carefully selected patients with delayed-type MPE, RDD appears to be a feasible and safe short-term strategy for enabling continuation of essential chemotherapy within the predefined observation period. As this pilot study includes a small and heterogeneous patient population with limited follow-up, the findings should be considered preliminary and hypothesis-generating and warrant confirmation in larger prospective studies with longer follow-up.<\/jats:p>","DOI":"10.3390\/jcm15166320","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:01:26Z","timestamp":1786968086000},"page":"6320","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Feasibility and Safety of Rapid Drug Desensitization for Chemotherapy-Induced Maculopapular Eruptions"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2915-6300","authenticated-orcid":false,"given":"Meryem","family":"Demir","sequence":"first","affiliation":[{"name":"Laboratory of Occupational & Environmental Respiratory Diseases and Asthma, Division of Immunology and Allergy, Department of Pulmonary Medicine, Faculty of Medicine, Ege University, 35100 Izmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilay","family":"Duman","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine, Ege University, 35100 Izmir, T\u00fcrkiye"},{"name":"Translational Pulmonary Research Center-EgeSAM, Ege University, 35100 Izmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haydar Soydaner","family":"Karakus","sequence":"additional","affiliation":[{"name":"Laboratory of Occupational & Environmental Respiratory Diseases and Asthma, Division of Immunology and Allergy, Department of Pulmonary Medicine, Faculty of Medicine, Ege University, 35100 Izmir, T\u00fcrkiye"},{"name":"Translational Pulmonary Research Center-EgeSAM, Ege University, 35100 Izmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1461-7485","authenticated-orcid":false,"given":"Sercan","family":"On","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Ege University, 35100 Izmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasim","family":"Okan","sequence":"additional","affiliation":[{"name":"Laboratory of Occupational & Environmental Respiratory Diseases and Asthma, Division of Immunology and Allergy, Department of Pulmonary Medicine, Faculty of Medicine, Ege University, 35100 Izmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatice Serpil","family":"Akten","sequence":"additional","affiliation":[{"name":"Laboratory of Occupational & Environmental Respiratory Diseases and Asthma, Division of Immunology and Allergy, Department of Pulmonary Medicine, Faculty of Medicine, Ege University, 35100 Izmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinem","family":"Inan","sequence":"additional","affiliation":[{"name":"Laboratory of Occupational & Environmental Respiratory Diseases and Asthma, Division of Immunology and Allergy, Department of Pulmonary Medicine, Faculty of Medicine, Ege University, 35100 Izmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8993-674X","authenticated-orcid":false,"given":"Su","family":"Ozgur","sequence":"additional","affiliation":[{"name":"Translational Pulmonary Research Center-EgeSAM, Ege University, 35100 Izmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuncay","family":"Goksel","sequence":"additional","affiliation":[{"name":"Laboratory of Occupational & Environmental Respiratory Diseases and Asthma, Division of Immunology and Allergy, Department of Pulmonary Medicine, Faculty of Medicine, Ege University, 35100 Izmir, T\u00fcrkiye"},{"name":"Translational Pulmonary Research Center-EgeSAM, Ege University, 35100 Izmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6180-713X","authenticated-orcid":false,"given":"Erdem","family":"Goker","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Ege University, 35100 Izmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Goksel","sequence":"additional","affiliation":[{"name":"Laboratory of Occupational & Environmental Respiratory Diseases and Asthma, Division of Immunology and Allergy, Department of Pulmonary Medicine, Faculty of Medicine, Ege University, 35100 Izmir, T\u00fcrkiye"},{"name":"Translational Pulmonary Research Center-EgeSAM, Ege University, 35100 Izmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/all.15113","article-title":"Hypersensitivity reactions to chemotherapy: An EAACI position paper","volume":"77","author":"Pagani","year":"2022","journal-title":"Allergy"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100640","DOI":"10.1016\/j.waojou.2022.100640","article-title":"Standards for practical intravenous rapid drug desensitization and delabeling: A WAO committee statement","volume":"15","author":"Broyles","year":"2022","journal-title":"World Allergy Organ J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/all.13562","article-title":"EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity","volume":"74","author":"Brockow","year":"2019","journal-title":"Allergy"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.3389\/fimmu.2017.01472","article-title":"Drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: The role of desensitizations","volume":"8","author":"Castells","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Vega, A., Pe\u00f1a, M.I., and Torrado, I. (2022). Use of rapid drug desensitization in delayed hypersensitivity reactions to chemotherapy and monoclonal antibodies. Front. Allergy, 2.","DOI":"10.3389\/falgy.2021.786863"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.18176\/jiaci.0335","article-title":"Successful bendamustine desensitization for a delayed-type hypersensitivity reaction","volume":"29","author":"Aradas","year":"2019","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1097\/CAD.0000000000000660","article-title":"Presentation and management of the delayed type of hypersensitivity reaction with bendamustine","volume":"29","author":"Shikdar","year":"2018","journal-title":"Anticancer Drugs"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.anai.2019.07.031","article-title":"A practical 16-day desensitization protocol in lenalidomide-induced non-immediate hypersensitivity reactions","volume":"123","author":"Demir","year":"2019","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/bjh.12925","article-title":"Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma","volume":"167","author":"Lee","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1111\/all.13765","article-title":"Immune pathomechanism and classification of drug hypersensitivity","volume":"74","author":"Pichler","year":"2019","journal-title":"Allergy"},{"key":"ref_11","first-page":"3","article-title":"Overview and unsuccessful outcomes of chemotherapy rapid drug desensitization. EAACI Congress Abstract Book. Flash Talk 001648","volume":"78","author":"Goksel","year":"2023","journal-title":"Allergy"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10147-014-0722-2","article-title":"Hypersensitivity to chemotherapeutics: A cross-sectional study with 35 desensitizations","volume":"20","author":"Goksel","year":"2015","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_13","first-page":"9","article-title":"Hypersensitivity Reactions to Taxanes: A Multicenter Study for Outcomes and Safety of Rapid Drug Desensitization","volume":"16","author":"Durmaz","year":"2024","journal-title":"Allergy Asthma Immunol. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/all.12142","article-title":"Skin test concentrations for systemically administered drugs: An ENDA\/EAACI Drug Allergy Interest Group position paper","volume":"68","author":"Brockow","year":"2013","journal-title":"Allergy"},{"key":"ref_15","unstructured":"National Cancer Institute Cancer Therapy Evaluation Program (2025, April 14). Common Terminology Criteria for Adverse Events and Common Toxicity Criteria [v5.0], Available online: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/trial-development."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaci.2008.02.044","article-title":"Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases","volume":"122","author":"Castells","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1081-1206(10)60016-6","article-title":"Desensitization to imatinib in patients with leukemia","volume":"97","author":"Nelson","year":"2006","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jaci.2004.04.029","article-title":"Clinical features and severity grading of anaphylaxis","volume":"114","author":"Brown","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Jimenez-Rodriguez, T.W., Manuel Marco de la Calle, F., Lozano-Cubo, I., Montoyo-Anton, R.A., Soriano-Gomis, V., Gonzalez-Delgado, P., Jos\u00e9, A.B.-S., Climent-Ballester, S., Mart\u00ednez-Banaclocha, N., and Fern\u00e1ndez-Sanchez, J. (2022). Converter phenotype: A new profile that is not exclusive to taxanes. Front. Allergy, 2.","DOI":"10.3389\/falgy.2021.785259"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Roger, I., Montero, P., P\u00e9rez-Leal, M., Milara, J., and Cortijo, J. (2023). Evaluation of Delayed-Type Hypersensitivity to Antineoplastic Drugs-An Overview. Cancers, 15.","DOI":"10.3390\/cancers15041208"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000055363","article-title":"Hypersensitivity reactions to carboplatin administration are common but not always severe: A 10-year experience","volume":"61","author":"Polyzos","year":"2001","journal-title":"Oncology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/sj.bjc.6601155","article-title":"Hypersensitivity reactions related to oxaliplatin (OHP)","volume":"89","author":"Brandi","year":"2003","journal-title":"Br. J. Cancer"},{"key":"ref_23","first-page":"1671","article-title":"Hypersensitivity Reactions to oxaliplatin: Incidence and management","volume":"18","author":"Gowda","year":"2004","journal-title":"Oncology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.jaip.2019.12.032","article-title":"Allergy Evaluation of Hypersensitivity to Platinum Salts and Taxanes: A Six-Year Experience","volume":"8","author":"Pradelli","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1067\/mjd.2003.44","article-title":"Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: A prospective study of 54 patients","volume":"48","author":"Valeyrie","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.anai.2016.08.035","article-title":"Slow desensitization of imatinib-induced nonimmediate reactions and dynamic changes of drug-specific CD4+CD25+CD134+ lymphocytes","volume":"117","author":"Klaewsongkram","year":"2016","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"573573","DOI":"10.3389\/fphar.2020.573573","article-title":"An Updated Review of the Diagnostic Methods in Delayed Drug Hypersensitivity","volume":"11","author":"Copaescu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000078583","article-title":"Successful desensitization to fixed drug eruption: The presence of CD25+CD4+ T cells in the epidermis of fixed drug eruption lesions may be involved in the induction of desensitization","volume":"209","author":"Teraki","year":"2004","journal-title":"Dermatology"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Vultaggio, A., Matucci, A., Nencini, F., Bormioli, S., Vivarelli, E., and Maggi, E. (2020). Mechanisms of Drug Desensitization: Not Only Mast Cells. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.590991"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.5415\/apallergy.2019.9.e9","article-title":"Interleukin-10 is increased in successful drug desensitization regardless of the hypersensitivity reaction type","volume":"9","author":"Gelincik","year":"2019","journal-title":"Asia Pac. Allergy"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/16\/6320\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:26:10Z","timestamp":1786969570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/16\/6320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,15]]},"references-count":30,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["jcm15166320"],"URL":"https:\/\/doi.org\/10.3390\/jcm15166320","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,15]]}}}